SCHEMBL610343

SCHEMBL610343

CCN(CC)C(=O)Cc1c(-c2ccccc2)nc2ccc(C)nn12

nearest known ligand 0.64

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSPO P30536 7/20 0.58
GABRA2 P47869 1/20 0.51
GABRB2 P47870 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL611447 0.92 TSPO (0.69) TSPOGABRA2GABRB2
SCHEMBL609983 0.91 GABRA2 (0.62) TSPOGABRA2GABRB2
SCHEMBL612319 0.90 GABRA2 (0.56) TSPOGABRA2GABRB2
SCHEMBL610206 0.89 TSPO (0.70) TSPOGABRA2GABRB2
SCHEMBL612627 0.89 TSPO (0.70) TSPOGABRA2GABRB2
SCHEMBL612190 0.89 TSPO (0.70) TSPO
SCHEMBL611533 0.87 TSPO (0.71) TSPO
SCHEMBL612293 0.85 GABRA2 (0.48) TSPOGABRA2GABRB2
SCHEMBL611630 0.85 TSPO (0.51) TSPOGABRA2GABRB2
SCHEMBL27741209 0.85 AKT1 (0.45) GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101448831-B Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as GABA receptor ligands FERRER INT 2013-05-01 CN claimed
US-20120040979-A1 IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS FALCO JOSE LUIS (ES) 2012-02-16 US claimed
EP-2010536-B1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INT (ES) 2010-06-16 EP claimed
US-20090176788-A1 Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions FERRER INTERNACIONAL, S.A. (ES) 2009-07-09 US claimed
CN-101448831-A Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as gaba receptor ligands FERRER INT (ES) 2009-06-03 CN claimed
EP-2010536-A1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS Ferrer Internacional, S.A. (ES) 2009-01-07 EP claimed
EP-1845098-A1 Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands FERRER INTERNACIONAL, S.A. (ES) 2007-10-17 EP claimed
WO-2007110437-A1 IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INTERNACIONAL, S.A. (ES) 2007-10-04 WO claimed
US-8993562-B2 Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions FERRER INTERNACIONAL, S.A. (ES) 2015-03-31 US disclosed
CN-101448831-B Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as GABA receptor ligands FERRER INT 2013-05-01 CN disclosed
US-8153789-B2 Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions FERRER INTERNACIONAL, S.A. (ES) 2012-04-10 US disclosed
US-20120040979-A1 IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS FALCO JOSE LUIS (ES) 2012-02-16 US disclosed
EP-2010536-B1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INT (ES) 2010-06-16 EP disclosed
US-20090176788-A1 Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions FERRER INTERNACIONAL, S.A. (ES) 2009-07-09 US disclosed
CN-101448831-A Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as gaba receptor ligands FERRER INT (ES) 2009-06-03 CN disclosed
EP-2010536-A1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS Ferrer Internacional, S.A. (ES) 2009-01-07 EP disclosed
EP-1845098-A1 Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands FERRER INTERNACIONAL, S.A. (ES) 2007-10-17 EP disclosed
WO-2007110437-A1 IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INTERNACIONAL, S.A. (ES) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176788-A1 Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions GABRA5, GABRA1, GABRA2 TSPO 140/4885GABRA2 3/4885GABRB2 8/4885
US-20120040979-A1 IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS GABRA5, GABRA1, GABRA2 TSPO 140/4885GABRA2 3/4885GABRB2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.